Kenyon Farrow
Senior EditorKenyon is the senior editor of TheBody/TheBodyPro. He has a distinguished track record working in communities impacted by HIV as an activist, writer, and strategist, stretching back long before he joined our team in late 2017. Kenyon's work has been recognized by many institutions, including Out Magazine's "Out 100" and The Advocate's "40 Under 40." He was also named a "Modern Black History Hero" by Black Entertainment Television.
Latest by Kenyon Farrow
This Champion of Community’s Role in Clinical Trials Reflects on 40 Years of Fighting Medical Mistrust And Research Neglect
Wakefield retires from the HIV Vaccine Trials Network after 20 years of service.
Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
Does Taking HIV Meds Reduce the Odds of COVID-19? Experts Say, ‘Not So Fast’
A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
Are Providers Ignoring Anal Sex as a Health Care Issue for Women at Risk for HIV and Cancer?
Recent studies examine the role anal sex is playing in HIV rates and anal cancer among women.
COVID-19 Impacts Gay and Bisexual Men's Mental Health, Sexual Behavior, and Access to HIV/STI Services
This new study is the first to look at the impacts of the coronavirus pandemic on men who have sex with men.
COVID-19 is Devastating Black Communities. And amfAR Just Released New Data and a Website to Prove It.
Advocates hope the research study and dashboard can be used to mobilize needed resources to combat the new coronavirus pandemic.
We Need to Temper Expectations for Remdesivir as COVID-19 Treatment
Because the public is getting so many mixed messages, it’s our responsibility to provide clarity and moderate optimism.
Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
Raltegravir Not Linked to Birth Defects, Study Shows
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.